Experimental Dengue Vaccine Protects all Recipients in Human Trials


An experimental dengue vaccine, TV003 that was developed by Dr. Whitehead and his colleagues at NIAID’s Laboratory of Infectious Diseases along with scientists from the U.S. Food and Drug Administration Center for Biologics Evaluation and Research protected 100% of the vaccine recipients in a clinical trial. Volunteers in this trial were infected with dengue virus six months after receiving either the experimental dengue vaccine TV003 or a placebo injection. All 21 volunteers who received the vaccine, were protected from dengue infection, while all 20 placebo recipients developed dengue.